A large number of PET/SPECT imaging agents for PSMA have been described, and many excellent reviews have been published.107, -109 Currently, prospective imaging agents for PSMA have advanced to small-scale clinical studies, hopefully leading to large-scale studies to validate their use in the diagnosis of metastatic prostate cancer.110. The gene discussed is FOLH1; the disease is metastatic prostate carcinoma.